Cardiac arrhythmias

Articolo redatto e revisionato del Dott. Luca Moretti

Cardiac arrhythmias are abnormalities of the normal organization of the heartbeat caused by an abnormality in impulse formation, impulse propagation, or the temporal relationship among different regions of the heart. They may present as acceleration, slowing, an irregular sequence, or the occurrence of beats arising outside the physiological pacemaker. The term arrhythmia is therefore not synonymous with an irregular pulse: a re-entrant tachycardia may be extremely regular, whereas fluctuations in sinus rate during respiration, especially in young people, often belong to normal cardiovascular regulation. The clinically decisive distinction concerns the rhythm's ability to sustain adequate circulation and the significance of the condition producing it.

There is no single prevalence figure for arrhythmias. The result of any survey depends on the age of the population, the presence of heart disease, the duration of recording and the definition used: an electrocardiogram lasting a few seconds, 24-hour monitoring and an implantable device observe very different portions of the heart's electrical life. Premature beats may also be found in healthy people; paroxysmal tachycardias also affect young individuals without structural heart disease; atrial fibrillation and many bradyarrhythmias instead become more common with aging and the accumulation of cardiovascular disease. In the Framingham cohort, the remaining lifetime risk of developing atrial fibrillation from age 55 was on the order of one third, with important differences according to the risk-factor profile: an estimate of lifetime risk should not be confused with the proportion of people who have the arrhythmia at a given point in time.

The relevance of an arrhythmia emerges from the interaction of three elements: the electrical mechanism, the cardiac substrate and the body's response. A brief sequence of ectopic beats in a structurally normal heart does not have the same significance as a similar episode in the presence of an infarct scar; an apparently moderate rate may be poorly tolerated when ventricular filling depends heavily on atrial contraction. Moreover, subjective perception does not directly measure risk: some patients perceive isolated premature beats intensely, whereas others do not recognize prolonged episodes of atrial fibrillation or a progressive decrease in heart rate.

Assessment therefore requires linking the symptom to the recording, recognizing conditions that make treatment urgent and defining which goals are actually achievable. Control of palpitations, prevention of syncope, protection against thromboembolism and reduction of the risk of sudden death are distinct goals that may require different interventions in the same patient. Disappearance of a subjective symptom does not automatically demonstrate that all of these problems have been resolved.

Etiology, risk factors, pathogenesis and pathophysiology

Normal rhythm does not arise from a succession of neural commands directed to each heartbeat. Sinus-node cells have spontaneous electrical activity, modulated by the autonomic nervous system and metabolic conditions; the impulse then reaches the atrial myocardium, crosses the atrioventricular junction and is distributed to the ventricles through the His-Purkinje system. The stability of this sequence depends both on the properties of individual cells and on their connections within the tissue. A cellular abnormality may remain confined and clinically silent or may recruit a sufficient mass of myocardium to generate a premature beat and, under certain conditions, a sustained arrhythmia.

The distinction between trigger and substrate explains why the same exposure does not produce the same effects in every individual. A premature beat may represent only an occasional event, but it may also encounter a circuit predisposed to re-entry or a region with unstable repolarization. The substrate may be anatomical, such as a scar or an accessory atrioventricular connection, or predominantly functional, such as a heterogeneous distribution of refractoriness. Autonomic tone, preceding heart rate, temperature, electrolytes and drugs modify this interaction over time. For this reason, a person may live for a long time with a predisposition and experience the first episode only when facilitating conditions arise.

Automaticity is the ability of certain cells to reach threshold spontaneously for a new action potential. Acceleration of the sinus node during exercise or fever is an example of a physiologically appropriate increase in pacemaker activity; the emergence of a faster focus at another site may instead take control away from the sinus node. Cells that normally lack dominant automaticity may also acquire spontaneous activity under pathological conditions, especially when membrane potential and ion currents are altered. Tachycardias driven by automaticity may sometimes accelerate and decelerate progressively, but this behavior is a clue rather than independent proof of the mechanism.

In triggered activity, the new depolarization depends on a preceding action potential. Early afterdepolarizations develop before repolarization has ended and become particularly important when action-potential duration is excessive. Delayed afterdepolarizations occur after repolarization and are often linked to abnormal intracellular calcium handling. Calcium release from the sarcoplasmic reticulum may activate the sodium-calcium exchanger and generate a depolarizing current; if threshold is reached, a new impulse occurs. This relationship explains why adrenergic stimulation, calcium overload and certain drugs can promote arrhythmias through processes other than a simple increase in sinus rate.

Re-entry requires an activation wavefront to be able to return to tissue that has become excitable again and reactivate it. Unidirectional block and sufficiently slow conduction are classic conditions allowing this process to begin. The circuit may use recognizable anatomical structures, such as an accessory pathway and the normal atrioventricular junction, or pathways within atrial or ventricular myocardium with different conduction properties. In an infarct scar, bundles of surviving myocytes separated by fibrosis may create channels through which the impulse travels slowly. It is therefore not necessary for all diseased tissue to be electrically inactive: the discontinuous survival of conducting myocardium itself may permit the arrhythmia.

Fibrosis also plays an important role outside myocardial infarction. Expansion of interstitial tissue, cell loss and remodeling of connections between myocytes alter the speed and uniformity of propagation. In the atria, hypertension, valvular heart disease, heart failure and aging may promote dilation and remodeling; in the ventricles, genetic or acquired cardiomyopathies may create vulnerable areas even when ejection fraction is relatively preserved. A normal measure of systolic function therefore does not exclude every arrhythmogenic substrate, just as a reduced ejection fraction alone does not identify the type of arrhythmia that will develop.

Myocardial ischemia rapidly alters energy availability, ion concentrations and conduction properties. In the acute phase it may promote ectopy, ventricular tachycardias and ventricular fibrillation; after healing, the scar constitutes a different electrophysiological problem, more favorable to relatively stable circuits. The temporal distinction has practical consequences: correcting a coronary occlusion treats an important acute cause, but does not necessarily eliminate a pre-existing scar substrate. Similarly, an increase in troponin during tachycardia does not by itself prove plaque rupture, because myocardial injury may also result from an imbalance between oxygen demand and supply.

Inflammatory and infiltrative diseases may involve both the working myocardium and the specialized conduction system. Myocarditis may produce electrical instability during the active phase and leave residual scarring; sarcoidosis may combine atrioventricular block and ventricular arrhythmias; amyloidosis alters the mechanical and electrical properties of the heart. In these settings, an arrhythmia may be the first sign of a broader disease. Etiological investigation is particularly important when the presentation is disproportionate to age, when extracardiac manifestations coexist or when the electrocardiogram shows multiple abnormalities not explained by a single common cause.

In inherited diseases, the defect may involve ion channels, calcium-handling proteins, desmosomes or other components of myocardial structure and function. Channelopathies may manifest without evident macroscopic heart disease; some cardiomyopathies, by contrast, manifest with arrhythmias before mechanical dysfunction becomes recognizable. A family history of sudden death, unexplained syncope, defibrillator implantation at a young age or cardiomyopathy directs the investigation, but the absence of a known family history does not exclude a genetic condition. Incomplete penetrance, variable expressivity and de novo variants limit the value of a simply negative family history.

Abnormalities of potassium, magnesium and calcium interfere with excitability, conduction and repolarization. Hypokalemia may increase susceptibility to certain tachyarrhythmias, especially in the presence of QT-prolonging drugs; significant hyperkalemia may depress conduction and produce progressive QRS widening, bradyarrhythmias or cardiac arrest. The effect depends not only on the absolute value, but also on the rate of change, pH, renal function and concomitant therapies. Correction therefore requires identification of the overall disorder rather than assuming that any electrolyte supplementation is useful in the absence of a documented deficiency or specific indication.

Endocrine and systemic causes include conditions acting through different mechanisms. Excess thyroid hormone facilitates sinus tachycardia and atrial fibrillation; hypothyroidism may slow the rhythm and alter repolarization. Anemia, infection, hypovolemia, pain, hypoxemia and pulmonary embolism may produce compensatory sinus tachycardia. In these cases, the elevated rate is also an indicator of the body's response: reducing it without understanding the cause may worsen cardiac output or delay treatment of the responsible disease. A documented arrhythmia does not make investigation of the extracardiac conditions promoting it unnecessary.

Exposure to drugs deserves an assessment that includes recent prescriptions, dose changes, over-the-counter products and interactions. Beta-blockers, some calcium-channel blockers and digoxin may slow the rhythm or atrioventricular conduction; numerous cardiac and non-cardiac drugs can prolong the QT interval. Accumulation due to reduced renal or hepatic elimination may turn a previously tolerated treatment into a precipitating factor. Abrupt withdrawal of certain treatments or combination with sympathomimetic substances may also modify risk. A temporal relationship with a new drug is an important clue, but it must be assessed together with other possible causes.

Alcohol, stimulants and recreational drug use may promote arrhythmias through autonomic, toxic, ischemic or metabolic effects. An association between exposure and symptoms does not, however, justify imposing the same prohibitions indiscriminately on every patient: quantity, pattern of use and individual response matter. Insufficient sleep, stress and deconditioning may also increase awareness of the heartbeat or facilitate its acceleration. Assessment must distinguish what causes a documented arrhythmia from what heightens attention to an otherwise normal rhythm, without automatically reducing palpitations to a psychological phenomenon.

Sleep-disordered breathing links fluctuations in oxygenation, changes in intrathoracic pressure and autonomic instability. It may be associated with atrial arrhythmias and episodes of nocturnal slowing, but a recording of bradycardia during sleep does not by itself establish sinus-node disease. Obesity, hypertension, diabetes and heart failure also contribute to an environment favorable to cardiac remodeling. These factors do not carry the same weight for every arrhythmia: they are particularly important in the prevention and management of atrial fibrillation, whereas an accessory-pathway tachycardia may depend primarily on a connection present from birth.

Hemodynamic consequences arise from the relationship among heart rate, stroke volume and coordination of the cardiac chambers. A very rapid tachycardia shortens filling time and may impair coronary perfusion, especially when oxygen consumption increases at the same time. Bradycardia reduces cardiac output when the increase in stroke volume does not compensate for the decrease in beats. Loss of coordinated atrial contraction may be particularly important in the presence of diastolic dysfunction; atrioventricular dissociation may render the atrial contribution ineffective and cause contractions against closed valves. Tolerance therefore cannot be derived from a numerical threshold that is identical for everyone.

Finally, the arrhythmia itself may become a cause of remodeling. Persistent tachycardia, an excessive ventricular response or a high burden of certain premature beats may contribute to arrhythmia-induced cardiomyopathy. The resulting contractile dysfunction in turn facilitates new episodes, creating a bidirectional relationship. Suspicion should arise when the duration or burden of the disorder appears compatible with ventricular deterioration and when sufficient alternative explanations are lacking; evidence becomes stronger when recovery follows control of the arrhythmia. Reversibility may be incomplete, especially when underlying heart disease coexists or treatment is delayed.

Electrocardiographic expression and main clinical forms

The electrocardiogram describes the result of cardiac activation, but does not make every step that generates it directly visible. The P wave represents atrial depolarization; the QRS complex reflects ventricular activation; the PR interval encompasses propagation from the beginning of atrial activation to the beginning of ventricular activation. To recognize an arrhythmia, these elements must be observed as parts of a sequence. An abnormal ventricular rate, considered in isolation, does not reveal whether the problem originates in the atria, the atrioventricular junction or the ventricles, nor does it establish that the atria and ventricles are controlled by the same mechanism.

Sinus rhythm is recognized by a P-wave morphology and axis compatible with origin in the sinus node and a coherent relationship with ventricular activation, while accounting for any associated conduction disorders. Sinus acceleration often shows gradual changes with activity, respiration and autonomic tone. Persistence at rest requires assessment of its appropriateness to the context: a rapid sinus rhythm during hemorrhage does not have the same meaning as persistent tachycardia without an identifiable secondary factor. Sinus origin of the impulse is therefore an electrocardiographic description, not a sufficient explanation of the observed rate.

A supraventricular premature beat may anticipate atrial activation and reach the ventricles through normal conduction, or it may be conducted with aberrancy if a bundle branch is still refractory. It may also fail to conduct altogether. A premature atrial contraction may therefore produce a narrow QRS, a wide QRS or an apparent pause. When the premature P wave is hidden in the terminal portion of the T wave, the tracing may be mistakenly interpreted as sinus arrest or atrioventricular block. Searching for atrial activity before the pause prevents attribution to the conduction system of a disorder that has not been demonstrated.

In a premature ventricular beat, the impulse arises distal to the normal supraventricular origin and activates part of the myocardium through pathways different from the usual distribution of the Purkinje system. The QRS is frequently wide and accompanied by secondary discordant repolarization, but width alone is not a sufficient criterion in every situation. A premature ventricular contraction should also be described according to morphology, temporal distribution, relationship with exercise and percentage of total beats. A compensatory pause is common but not obligatory; some premature beats are interpolated or conduct retrogradely to the atria, altering the subsequent cycle.

A regular narrow-QRS tachycardia generally indicates that the ventricles are being activated through the specialized conduction system in a relatively rapid and coordinated manner. Possibilities include atrioventricular nodal re-entrant tachycardia, orthodromic atrioventricular re-entrant tachycardia, atrial tachycardias and flutter with fixed conduction. The position of the P wave relative to the QRS and the relationship between RP and PR intervals guide the reasoning, but the P wave may be hidden within the QRS or T wave. A rate near 150 beats per minute should also prompt consideration of flutter with 2:1 conduction, without turning this value into an absolute diagnostic rule.

In atrioventricular nodal re-entrant tachycardia, the circuit involves structures in the nodal region with different functional properties. Atrial and ventricular activation may be nearly simultaneous, making it difficult to distinguish a separate P wave. Atrioventricular re-entrant tachycardia instead uses an accessory connection as part of the circuit: in the orthodromic form, the impulse reaches the ventricles through the normal junction and returns to the atria through the accessory pathway. A pathway that conducts only retrogradely may sustain this arrhythmia without producing pre-excitation during sinus rhythm. The absence of a delta wave on the baseline tracing therefore does not exclude every accessory-pathway tachycardia.

Atrial tachycardias are sustained by activity originating in the atria and do not necessarily require ventricular participation to continue. This property explains why transient slowing of atrioventricular conduction may make atrial waves more visible without terminating the arrhythmia. In atrial flutter, a macro-reentrant circuit produces organized atrial activation; the ventricular rate depends on the conduction ratio. The typical form is linked to a right atrial circuit involving the cavotricuspid isthmus, whereas other forms may use surgical scars, ablation lesions or different atrial substrates. The appearance of atrial waves is informative, but does not always identify the anatomy of the circuit with certainty.

Completely irregular ventricular intervals, in the absence of repetitive organized P waves, are characteristic of atrial fibrillation when atrioventricular conduction is variable. Not every irregularity, however, is fibrillation: frequent premature beats, multifocal atrial tachycardia and changes in the conduction ratio of flutter can produce irregular rhythms. Conversely, atrial fibrillation may be associated with a regular ventricular rhythm when complete atrioventricular block occurs or when artificial pacing governs the ventricles. Diagnosis therefore requires examination of atrial activity and clinical context in addition to simple observation of the sequence of RR intervals.

A wide-QRS tachycardia opens a differential diagnosis in which ventricular tachycardia must retain a prominent position, especially in the presence of structural heart disease. Other possibilities include supraventricular tachycardia with pre-existing or functional bundle branch block, tachycardia with pre-excitation, and rhythms affected by drugs, metabolic disorders or artificial pacing. The fact that the patient is conscious and has preserved blood pressure does not exclude ventricular tachycardia. In managing an episode of uncertain origin, assuming a ventricular origin provides a prudent orientation because some treatments appropriate for supraventricular tachycardias may be dangerous if applied to the wrong diagnosis.

Atrioventricular dissociation, capture beats and fusion beats may provide evidence supporting a ventricular origin. With capture, a supraventricular impulse occasionally succeeds in activating the ventricles; with fusion, activation results from the combination of two wavefronts. However, their absence does not exclude ventricular tachycardia, and a 1:1 atrioventricular relationship does not establish a supraventricular origin because retrograde conduction may be present. Algorithms based on QRS morphology and intervals are useful tools, but are affected by tracing quality, interpretive experience and particular conditions such as pre-excitation or antiarrhythmic therapy.

Monomorphic ventricular tachycardia has complexes with relatively stable morphology, reflecting a repeating activation sequence. It may depend on a scar-related circuit, but idiopathic forms without evident structural heart disease also exist. In polymorphic forms, morphology changes from beat to beat; significance also depends on the preceding QT interval, the presence of ischemia and the circumstances of the episode. Torsades de pointes is a specific polymorphic ventricular tachycardia associated with QT prolongation: using this term for any polymorphic tachycardia may lead to treatment inappropriate for the actual mechanism.

Duration distinguishes brief episodes from persistent arrhythmias, but must be interpreted together with the need for intervention. For ventricular tachycardias, the conventional definition of sustained includes episodes lasting at least 30 seconds and those requiring earlier termination because of hemodynamic compromise. A shorter sequence is not automatically without significance: non-sustained ventricular tachycardia requires assessment of the substrate and clinical context. Rate, morphology, symptoms, relationship with exercise and family history modify its prognostic weight more than an isolated label.

In bradyarrhythmias, it is essential to separate a reduced rate of atrial activation from an obstacle to impulse transmission to the ventricles. If the P waves slow together with the QRS complexes, the problem may involve the sinus node or its modulation; if the P waves continue at their own rate and some or all impulses fail to reach the ventricles, an atrioventricular disorder should be considered. A junctional or ventricular escape rhythm may maintain a residual rate, but its presence does not guarantee stability. QRS width, regularity and response to autonomic changes contribute to localization without replacing the overall assessment.

Pauses require analysis of the preceding and subsequent sequence. They may follow termination of an atrial tachyarrhythmia, result from vagal slowing, arrest of impulse formation, block of its exit from the sinus node or failure of conduction of an atrial impulse. Chronotropic incompetence, by contrast, represents defective adaptation of heart rate to demand and may escape detection on a tracing obtained at rest. A useful clinical classification must therefore encompass not only what the heart does at a given moment, but also what it fails to do when metabolic requirements increase.

Arrhythmia burden completes the description without replacing the type of rhythm. It may be expressed as the percentage of ectopic beats, time spent in a given arrhythmia, or the number and duration of episodes. These measures are not interchangeable: ten episodes lasting a few seconds do not equal one episode lasting many hours, and a daily percentage of premature beats may vary considerably between recordings. Moreover, the burden that justifies intervention depends on the objective: relieving symptoms, preventing cardiomyopathy and reducing embolic risk require different interpretations. Numerical precision should not conceal the biological and temporal uncertainty of the measurement.

Clinical manifestations

The clinical history begins with the patient's own description of the episode and then seeks to reconstruct its temporal sequence. Palpitations may be described as missed beats, isolated thumps, vibrations, sudden accelerations or particularly forceful pulsations. These sensations do not correspond uniquely to an arrhythmia: the perception of a skipped beat may result from the premature beat, the subsequent pause or the more forceful post-extrasystolic beat. A patient describing a very forceful heartbeat may have a normal rate; another may perceive bigeminy as slow when many premature beats fail to generate an appreciable peripheral pulse wave.

The onset and termination help formulate hypotheses. An abrupt transition from the usual rhythm to a rapid, regular sequence, with equally abrupt termination, is compatible with a paroxysmal re-entrant tachycardia. Progressive acceleration during activity, fever or stress more often suggests a sinus response, but does not prove it; some atrial tachycardias may have a gradual pattern. It is useful to know whether the episode begins with a single beat, whether it recurs with identical characteristics and whether the patient can identify a precise moment of termination. Reconstruction must nonetheless allow for uncertainty of memory and the difficulty of estimating heart rate without a recording.

The duration and frequency of attacks affect both their clinical impact and the likelihood of documenting them. Episodes lasting a few seconds several times a day pose a different problem from a prolonged monthly attack. The relationship with exercise, recovery, nocturnal rest, meals, posture or medication use may suggest a role for autonomic or metabolic stimuli. Tachycardia occurring only in the upright position also requires assessment of the blood-pressure response and volume status; an arrhythmia emerging during exertion, especially when associated with syncope or chest pain, increases the importance of investigating heart disease or an inherited predisposition. None of these relationships, by itself, replaces an ECG tracing.

Neck pulsations may accompany certain regular tachycardias, particularly when atrial contraction occurs against closed atrioventricular valves. The patient may report a visible cervical pulsation or a pounding sensation different from chest palpitations. Polyuria after a prolonged episode may also occur in relation to hemodynamic changes and release of natriuretic peptides. These elements enrich the history but should not be turned into pathognomonic signs: different mechanisms may produce overlapping manifestations, and their absence does not decisively reduce the probability of a tachycardia.

Dyspnea may reflect reduced cardiac output, increased filling pressures, ischemia or concomitant respiratory disease. In rapid arrhythmias, the patient may suddenly stop activity because of shortness of breath; in bradyarrhythmias or chronotropic incompetence, the patient may describe a progressive inability to sustain previously tolerated effort. When atrial fibrillation is persistent, fatigue and reduced exercise capacity may predominate over palpitations. The development of orthopnea, dyspnea at rest or rapidly developing congestion points toward hemodynamic compromise requiring prompt assessment, without assuming that the respiratory disturbance depends exclusively on the rhythm.

Chest pain during tachycardia may result from increased myocardial demand, but may also indicate primary ischemia that precipitated the arrhythmia. Chronology is therefore crucial: pain that precedes acceleration, persists after it ends, or occurs in a patient with a high probability of coronary artery disease should not automatically be explained by the rapid heartbeat. Pain characteristics, serial electrocardiograms and biomarker trends all contribute to assessment. The same attention is required when the patient reports pleuritic pain, sudden dyspnea or signs suggesting an urgent extracardiac cause.

Presyncope includes sensations of impending loss of consciousness, visual dimming and instability that may accompany a transient reduction in cerebral perfusion. Syncope is instead a brief loss of consciousness with rapid onset and spontaneous recovery, caused by global cerebral hypoperfusion. When an arrhythmic origin is possible, occurrence during exercise or in the supine position, absence of a usual prodrome, immediately preceding palpitations and the presence of heart disease are relevant. However, no single feature can attribute the event to the heart with certainty; reflex syncope and orthostatic hypotension may coexist with an incidentally recorded arrhythmia.

A witness's description helps distinguish apparent duration, skin color, movements and mode of recovery. Brief myoclonic movements may also occur during syncope and do not necessarily establish epilepsy. Conversely, prolonged confusion after the event, focal neurological symptoms or other atypical features require an appropriate differential diagnostic pathway. Unremembered falls in older people may represent unrecognized syncope, especially when no witness is present. Analysis must therefore integrate the circumstances with frailty, balance disorders and medication use, avoiding both failure to recognize an intermittent arrhythmia and attribution of every fall to it.

In bradyarrhythmias, fatigue may be the predominant symptom and follow an insidious course. The patient spontaneously reduces activity, attributing the limitation to age, and does not identify a precise episode. A pause after termination of a tachyarrhythmia may instead cause a sudden sensation of emptiness, dizziness or loss of consciousness. In bradycardia-tachycardia syndrome, the most relevant disturbance may occur precisely when the palpitations end. Asking only how the patient feels during the acceleration risks missing this clinically decisive phase.

Arrhythmias may also be asymptomatic and detected during an examination, monitoring or device interrogation. The absence of symptoms does not eliminate the need to interpret atrial fibrillation, a significant block or ventricular tachycardia; at the same time, a brief automatically recorded abnormality does not justify a serious diagnosis without confirmation. It is important to establish why monitoring was performed and what question it was intended to answer. The value of an incidental finding depends on its quality, duration, reproducibility and prior clinical probability.

The past medical history reconstructs myocardial infarction, heart failure, valvular heart disease, congenital heart disease, surgery, previous ablations and systemic diseases. A surgical atrial scar may predispose to macro-reentry many years after the procedure; a cardiomyopathy may previously have been described in general terms that deserve clarification through documentation. The medication history includes adherence, doses, recent diarrhea or vomiting, changes in renal function and possible overlapping drug therapies. In the family history, it is useful to specify the age and circumstances of events because unexplained nocturnal death, drowning or an isolated accident may require a different interpretation from known cardiovascular death at an advanced age.

Emotional state and the impact on daily life should be explored without prejudice. Anxiety and hypervigilance may intensify awareness of the heartbeat and promote sinus tachycardia, but may also develop after genuine and unpredictable arrhythmic episodes. Avoidance of exercise, interruption of work and continual checking of a wearable device may become a relevant part of the problem. A correct assessment does not automatically oppose a cardiac cause to a psychological one: it seeks objective correlation of episodes and recognizes that several factors may contribute to symptoms at the same time.

The physical examination begins with overall stability: level of consciousness, peripheral perfusion, blood pressure, respiratory rate and signs of respiratory distress. A blood-pressure value that is still preserved does not exclude evolving compromise, especially if the patient is cold, confused or has ischemic pain and congestion. Heart rate should be measured at the heart and compared with the pulse when a peripheral pulse deficit is suspected. Pulse regularity guides suspicion, but auscultation does not replace electrocardiographic identification. Finding a normal rate at the time of examination does not refute a paroxysmal disorder.

Cardiovascular examination looks for murmurs, a third heart sound, jugular venous distention, edema and other clues to heart disease or congestion. Marked variations in the intensity of the first heart sound and intermittent jugular pulsations may suggest atrioventricular dissociation, but are often difficult to recognize. Pallor, tremor, thyroid signs, fever, dehydration and respiratory findings point toward causes or facilitating factors. When circumstances warrant, measurement of blood pressure and heart rate in the supine and standing positions helps distinguish a postural response from a primary arrhythmia. The significance of each finding depends on its concordance with the history and with the rhythm actually recorded.

Clinical assessment concludes by defining the priority of care. Loss of consciousness, signs of shock, persistent ischemic pain, pulmonary edema or severe alteration in mental status associated with an abnormal rhythm require urgent intervention. A stable patient with brief episodes and no known heart disease may instead follow a scheduled diagnostic pathway, provided risk features have been considered. The distinction does not simply separate symptomatic and asymptomatic patients: it concerns the probability that the rhythm compromises circulation or signals a potentially dangerous disease, even when the subjective disturbance appears modest.

Investigations and diagnosis

Diagnosing an arrhythmia requires answering distinct questions: which rhythm is present, whether that rhythm explains the symptoms, which condition promoted it and what risk it carries. There are no single diagnostic criteria applicable to all cardiac arrhythmias because the term encompasses very different electrophysiological phenomena. The pathway begins with clinical assessment and the electrocardiogram, proceeds with monitoring proportionate to episode frequency, and expands only when the substrate needs to be characterized or the mechanism clarified. An indiscriminate sequence of tests may produce incidental findings without resolving the original question.

A twelve-lead electrocardiogram during symptoms often provides the most important information. When circumstances allow, it is useful to acquire the tracing before terminating the arrhythmia and to preserve a complete copy, without delaying necessary treatment. A single-lead monitor strip may document rate and pattern but may fail to show atrial waves or the morphological characteristics essential to differential diagnosis. The tracing after termination is also informative: it may show pre-excitation, repolarization abnormalities, signs of previous myocardial infarction or conduction abnormalities that alter interpretation of the episode.

Systematic analysis considers recording quality, atrial and ventricular rate, regularity, P-wave morphology, the P-QRS relationship, QRS duration and repolarization. Paper speed, calibration and correct electrode placement should be verified before assigning significance to unusual intervals or morphologies. Tremor, muscle activity, movement and intermittent contact may mimic flutter, fibrillation or ventricular tachycardia. The presence of normal complexes continuing through an apparent arrhythmic sequence, or of a normal rhythm in a simultaneous lead, may reveal an artifact. Discordance with the pulse and clinical status calls for immediate verification rather than automatic acceptance of the alarm.

On the baseline tracing, a short PR interval with a delta wave suggests ventricular pre-excitation; a clearly prolonged corrected QT may point toward repolarization vulnerability; particular abnormalities in the right precordial leads may require assessment for Brugada syndrome. These findings should be interpreted taking drugs, electrolytes, temperature and recording conditions into account. Long QT syndrome does not coincide with every elevated automated QTc measurement, just as electrocardiographic pre-excitation does not establish that every palpitation experienced by the patient is caused by the accessory pathway.

Measurement of the QT requires a clearly readable T wave and a consistent method. Correction formulas do not completely eliminate rate dependence: the Bazett formula tends to overcorrect at high rates and undercorrect at low rates. A wide QRS, U waves, alternating cycle lengths and atrial fibrillation make assessment more complex. For this reason, an important clinical decision should not be based solely on the value printed by the electrocardiograph. Comparison with previous tracings, manual examination and, when necessary, specialist assessment clarify whether the change is real and how much is due to depolarization or repolarization.

When the arrhythmia is not present during the visit, ambulatory monitoring should be selected according to the probability of capturing it. A 24- or 48-hour Holter monitor is reasonable when symptoms occur daily or very frequently; recordings lasting several days increase the likelihood of capturing less frequent episodes and may characterize their burden better. Event recorders and loop-memory systems are suited to different questions: some require activation by the patient, whereas others automatically retain sequences preceding and following a detected event. The useful duration of monitoring depends on the actual frequency of manifestations, not merely on availability of the device.

A symptom diary and time marking are essential for establishing correlation. A recording showing sinus rhythm during the typical episode can exclude a tachyarrhythmia as the immediate explanation for that episode; it does not necessarily exclude different manifestations at other times. Normal monitoring during a period without symptoms has limited ability to exclude a paroxysmal arrhythmia. Premature beats occurring at another time do not establish that they caused a syncopal episode. The report should distinguish simple coexistence from a plausible temporal relationship between rhythm and clinical manifestation.

An implantable cardiac monitor may be useful when clinically important episodes, especially syncope, are too infrequent to be captured by external recordings and when the diagnostic probability and impact of the answer justify implantation. It is not the initial solution for every occasional palpitation. In patients who already have a pacemaker or defibrillator, interrogation may provide valuable electrograms and temporal data, but automatically classified episodes require review. Oversensing, noise, premature beats or lead problems may be labeled as arrhythmias; the category assigned by the device is not always equivalent to a confirmed clinical diagnosis.

Wearable devices may record an electrocardiographic signal or estimate the pulse by photoplethysmography. The distinction is fundamental: a notification of pulse irregularity does not necessarily identify the electrical mechanism and may be influenced by movement, peripheral perfusion or premature beats. A readable single-lead ECG may help document an episode, but does not reproduce all of the information from twelve leads and is not suitable for excluding every arrhythmia or heart disease. Clinical interpretation considers the quality, duration and context of the recording; an isolated automated notification should not by itself become the basis for initiating treatment with important consequences.

For atrial fibrillation, electrocardiographic documentation must show activity compatible with the disorder and be verified by a healthcare professional. Time thresholds used to classify brief recordings do not have the same meaning as the duration required to decide on therapy. Device-detected atrial high-rate episodes also constitute a category that requires signal confirmation and interpretation of burden. Distinguishing clinically documented atrial fibrillation, a subclinical episode and a simple irregularity notification prevents automatic transfer of the same decisions about embolic risk to all of these situations.

Blood tests are selected according to clinical suspicion. A complete blood count, electrolytes and renal function may identify anemia, metabolic abnormalities or conditions that alter medication safety; thyroid function is particularly relevant in atrial tachyarrhythmias and when clinical clues to endocrine dysfunction are present. Magnesium, calcium, blood-gas analysis and other tests are indicated in specific circumstances. Toxicological, infectious or inflammatory testing is not a mandatory panel for every arrhythmia, but may be decisive when the history, age or presentation suggests a specific cause.

Troponin should be ordered and interpreted in relation to the probability of myocardial injury and coronary syndrome. Sustained tachycardia may be associated with an increase in the biomarker without acute coronary thrombosis; conversely, attributing every increase to heart rate may miss an ischemic diagnosis. The overall picture of symptoms, electrocardiographic changes, biomarker kinetics and patient characteristics matters. Natriuretic peptides and other markers may contribute to assessment of heart failure, but do not by themselves identify the mechanism of the arrhythmia or establish which process began first.

Echocardiography assesses chamber dimensions, systolic function, valves and possible signs of structural heart disease. It is particularly useful when the arrhythmia is persistent, when signs of heart failure appear, when the clinical examination or ECG is abnormal, or when the type of arrhythmia makes cardiac characterization necessary. A normal echocardiogram reduces the probability of many forms of heart disease but does not exclude limited scars, early inflammation or channelopathies. In very irregular rhythms, measurement of ventricular function requires care in selecting cycles; a single nonrepresentative beat may distort the estimate.

Cardiac magnetic resonance imaging adds tissue characterization that is useful when cardiomyopathy, myocarditis, infiltration or scars not well defined on echocardiography are suspected. Late gadolinium enhancement may identify areas of fibrosis or injury with distributions that help orient etiology, but the finding must be interpreted together with the history and other tests. MRI is not necessary for every isolated premature beat in a low-risk patient; it may instead be appropriate when arrhythmia morphology is unusual, burden is substantial, ventricular function is abnormal or there are clues to disease despite an unremarkable echocardiogram.

Coronary assessment addresses a specific question of ischemia or atherosclerotic disease. Functional tests, coronary computed tomography angiography and invasive coronary angiography are not interchangeable and are selected according to presentation, clinical probability and urgency. A ventricular arrhythmia during acute chest pain poses a different problem from chronic premature beats in the absence of ischemic symptoms. Even in known coronary artery disease, an active ischemic factor should be distinguished from a circuit using a stable scar: the diagnostic answer changes expectations regarding revascularization.

An exercise test allows observation of the heart-rate response, possible development of arrhythmias and their relationship to symptoms in a controlled environment. It may be particularly informative for exercise-related palpitations, suspected chronotropic incompetence or specific adrenergic arrhythmias. Failure to reproduce the episode does not exclude every intermittent disorder, and a reduced chronotropic response should be interpreted by considering the workload actually achieved, age, medications and concomitant diseases. When the presentation raises suspicion of high risk, the indication for and method of testing require prior specialist assessment.

An electrophysiology study uses intracardiac recordings and programmed stimulation to clarify circuits, conduction properties and inducibility of certain arrhythmias. It is particularly useful when definition of the mechanism may be followed by ablation, or in specific risk-stratification pathways. It is not a general test capable of excluding all arrhythmias if the result is negative. Failure to induce an arrhythmia may depend on the mechanism, testing conditions and medications; inducibility, in turn, must be linked to the clinical picture and the type of rhythm provoked, without automatically equating it with the spontaneous episode.

Genetic testing is indicated when the phenotype or family history suggests an inherited disease in which the result may contribute to diagnosis, management or family evaluation. Gene selection, counseling and specialist interpretation are part of the test. A variant of uncertain significance does not establish the cause of the arrhythmia and should not be used as though it were a pathogenic variant for irreversible decisions or to classify relatives. A negative result does not eliminate every genetic possibility because knowledge of genes and mechanisms remains incomplete and some conditions have complex bases.

The differential diagnosis includes physiological rhythms that are perceived intensely, secondary sinus tachycardia, orthostatic syndromes, reflex syncope, neurological events and symptoms caused by respiratory or metabolic disorders. The cardiac finding itself must also be distinguished from conditions that mimic it: blocked premature atrial contractions may simulate pathological pauses; aberrant conduction may mimic ventricular ectopy; artifacts may simulate a dangerous tachycardia. Reasoning proceeds by determining which explanation makes the tracing, history and hemodynamic behavior coherent, without selecting a diagnosis solely on the basis of the most conspicuous finding.

Risk stratification concludes and accompanies the diagnostic pathway. It considers structural heart disease, ventricular function, scar, symptoms, characteristics of the arrhythmia, family history and specific inherited conditions. There is no single score valid for all arrhythmias; tools developed for thromboembolic risk in atrial fibrillation do not measure the risk of ventricular tachycardia, and parameters used to prevent sudden death do not automatically determine the indication for anticoagulation. The report and clinical assessment should make explicit which risk has been estimated and which elements remain to be clarified.

Treatment and prognosis

Therapeutic choice derives from the combination of rhythm diagnosis, hemodynamic status, underlying heart disease and treatment objective. Not all arrhythmias require pharmacological suppression, and normalization of the tracing does not always coincide with improved prognosis. An intervention may aim to terminate a dangerous episode, reduce recurrences, correct an inappropriate heart rate, prevent embolism or protect against lethal ventricular arrhythmias. Making the objective explicit allows benefits and risks to be assessed consistently and helps explain why two patients with the same diagnostic label may receive different treatments.

In hemodynamic instability, the priority is circulatory support and identification of immediately reversible causes. An arrhythmia may be responsible for the instability or may accompany shock caused by hemorrhage, sepsis, ischemia or other conditions; this distinction affects treatment. Compensatory sinus tachycardia is not usefully resolved by cardioversion. When, by contrast, a tachyarrhythmia is causing severe compromise, synchronized electrical cardioversion is an essential intervention. Sedation and analgesia are considered in the conscious patient according to clinical conditions, without delaying an urgent procedure when perfusion is threatened.

Synchronized cardioversion coordinates the shock with the QRS complex to reduce the risk of delivering it during a vulnerable phase of repolarization. Defibrillation instead uses an unsynchronized shock and is indicated for shockable cardiac-arrest rhythms such as ventricular fibrillation and pulseless ventricular tachycardia. In unstable polymorphic ventricular tachycardias, synchronization may be unreliable and management requires the electrical mode appropriate to the rhythm. The presence or absence of a pulse and the quality of perfusion are therefore decisive information; a monitor trace cannot be treated independently of patient assessment.

Symptomatic bradycardia with compromised perfusion requires monitoring, treatment of the cause and, when necessary, pharmacological support or temporary pacing. Atropine may be useful in certain forms, especially when a vagal or nodal component is relevant, but may be ineffective in distal blocks. Failure to respond should not delay use of appropriate support strategies. With transcutaneous pacing, appearance of an electrical complex after the pacing stimulus is not enough: mechanical capture with improved circulation must be verified. Temporary transvenous pacing is reserved for situations in which the expected benefit justifies invasiveness and complications.

In a clinically stable regular narrow-QRS tachycardia, vagal maneuvers may terminate a circuit that depends on atrioventricular conduction. The modified Valsalva maneuver showed greater efficacy than the standard technique in the REVERT trial when performed according to a controlled protocol in selected patients. The response also has interpretive value: transient slowing may make previously hidden atrial activity visible without terminating it. The choice of maneuver and any contraindications depend on the context; not all procedures that increase vagal tone have the same safety profile.

Adenosine produces very brief atrioventricular block and can terminate tachycardias in which the atrioventricular node is a necessary part of the circuit. It is used in a monitored setting with treatment for complications readily available. It is not a generic treatment for every rapid or irregular rhythm: in pre-excited atrial fibrillation, blocking nodal conduction may promote dangerous ventricular conduction through the accessory pathway. Bronchospasm, specific drug interactions and individual conditions also influence the choice. The benefit of administration must be assessed in relation to the rhythm actually suspected, not merely the heart-rate value.

A wide-QRS tachycardia of uncertain origin is managed with particular caution. Initial stability allows information to be acquired, but does not make empirical administration of any drug used for supraventricular tachycardias appropriate. Verapamil and other drugs that may depress hemodynamic function or conduction should not be used indiscriminately as a diagnostic trial. Treatment of a tolerated monomorphic ventricular tachycardia may include cardioversion or an antiarrhythmic drug selected according to heart disease, ventricular function, blood pressure, QT interval and local availability. Continuous monitoring is necessary because an initially stable condition may deteriorate during the episode or treatment.

In torsades de pointes, recognition of a prolonged QT changes the strategy: precipitating drugs are withdrawn, electrolyte disturbances are corrected, and magnesium is used according to the clinical context. In recurrent acquired forms promoted by pauses, it may be necessary to increase the heart rate by pacing or other specialist measures. This logic cannot be transferred indiscriminately to polymorphic tachycardias with a normal QT, in which ischemia and other mechanisms carry different weight, nor to congenital forms without considering the specific syndrome. In the presence of instability or cardiac arrest, electrical treatment retains priority.

Once the emergency has been overcome, correction of causes may reduce or eliminate the disorder. Treating hyperthyroidism, hypoxemia, significant anemia, volume depletion or drug toxicity acts on the precipitating mechanism. In arrhythmias associated with heart disease, treatment of heart failure, ischemia or valvular disease helps modify the substrate. Reversibility must nevertheless be verified over time: a drug may have unmasked a pre-existing conduction disease, and an episode facilitated by an acute cause may reveal a predisposition that persists after that cause is corrected. Termination of the arrhythmia does not automatically conclude the assessment.

For premature beats in the absence of heart disease and risk features, an accurate explanation of the phenomenon may constitute a substantial part of treatment. The decision to intervene depends on symptoms, burden, ventricular function and type of ectopy. Suppression of every premature beat is not a universal goal; beta-blockers, other selected drugs or ablation are considered when the disorder is clinically important or contributes to cardiac dysfunction. Benefit should be documented against the original problem: a modest numerical reduction may accompany a major subjective improvement, whereas a marked reduction may fail to resolve symptoms caused by another condition.

Antiarrhythmic drugs modify excitability, conduction, refractoriness or autonomic response. Pharmacological classification is useful for understanding mechanisms but does not replace assessment of the individual drug. Selection takes into account ischemic heart disease, scar, ventricular function, renal and hepatic function, QT interval, baseline heart rate and interactions. The safety of flecainide or propafenone in selected settings cannot be extended to patients with major ischemic or structural substrates; the CAST trial demonstrated that suppressing ectopy after myocardial infarction with certain class Ic drugs can increase mortality. Control of the arrhythmia is therefore an intermediate outcome, distinct from the overall clinical outcome.

Therapy monitoring includes ECG and assessments targeted to the molecule being used. An increase in QRS duration may signal an excessive effect on conduction; QT prolongation, especially together with bradycardia or electrolyte abnormalities, may indicate greater vulnerability to proarrhythmia. Some drugs require monitoring of thyroid, hepatic, pulmonary or renal function. Amiodarone has considerable efficacy in several settings, but its long half-life, interactions and extracardiac toxicity condition its use. Monitoring does not concern only treatment initiation: an infection, dehydration or a new drug may change the risk profile after months of apparent stability.

In atrial fibrillation, rate control aims to limit the ventricular response, whereas rhythm control seeks to restore and maintain sinus rhythm. The two approaches are not necessarily mutually exclusive throughout life: they may be combined or changed as the clinical picture evolves. The choice of drugs that slow atrioventricular conduction depends mainly on ventricular function, blood pressure, physical activity and comorbidities. An acceptable heart rate at rest may be insufficient to describe control during exercise; persistent symptoms or suspected cardiomyopathy require a broader reassessment than the single number measured in the clinic.

Rhythm control becomes particularly relevant when the arrhythmia causes symptoms, functional deterioration or potentially reversible ventricular dysfunction. The EAST-AFNET 4 trial showed benefit from an early strategy in patients with recently diagnosed atrial fibrillation and associated cardiovascular conditions, through a pathway that included drugs and, when indicated, ablation. This finding supports timely assessment of the option, but does not establish that every patient should receive the same drug or procedure. Disease duration, atrial size, comorbidities, probability of maintaining sinus rhythm and informed preferences contribute to the decision.

Cardioversion of atrial fibrillation requires specific assessment of thromboembolic risk, the known or presumed duration of the episode and anticoagulation already being taken. When a safety condition for early cardioversion is not met, the pathway may include an adequate period of anticoagulation or a targeted examination to exclude intracardiac thrombi, according to clinical indications. Return of sinus electrical activity does not produce immediate recovery of atrial mechanical function: atrial stunning contributes to risk during the following weeks. Antithrombotic protection before and after the procedure must therefore be planned even when cardioversion appears technically simple or the episode is only mildly symptomatic.

Anticoagulation in atrial fibrillation is decided according to the individual's risk of stroke and thromboembolism, while simultaneously assessing bleeding risk, renal function, interactions and the feasibility of adherence. Classification of the arrhythmia as paroxysmal or persistent and the apparent success of rhythm control do not replace this assessment. In the 2024 European guidelines, the CHA2DS2-VA score considers heart failure, hypertension, age, diabetes, previous thromboembolic events and vascular disease: anticoagulation is recommended from two points and should be considered with one point, within an individualized decision. Risk factors change over time and require reassessment, including in those who initially have a low-risk profile.

Direct oral anticoagulants are generally preferred to vitamin K antagonists in eligible patients, but important exceptions exist, such as mechanical prosthetic heart valves and moderate or severe mitral stenosis. Dose and choice of agent follow specific criteria that include renal function, age, weight and interactions; an unjustified dose reduction is not a reliable strategy for making treatment safer. Antiplatelet agents are not an equivalent substitute for anticoagulant prevention of atrial-fibrillation-related stroke. If an antiplatelet indication also exists, for example after a coronary procedure, the combination and its duration require dedicated planning to limit bleeding risk.

Subclinical atrial episodes detected by devices require greater attention to the absolute balance between benefits and harms. In ARTESiA, apixaban reduced stroke and systemic embolism compared with aspirin in a selected population with subclinical atrial fibrillation, while increasing major bleeding. In NOAH-AFNET 6, edoxaban did not significantly reduce the primary composite outcome in patients with atrial high-rate episodes and worsened the composite safety outcome. Differences between populations, comparators and outcomes preclude an oversimplified reading of the two trials; above all, they do not justify automatic anticoagulation after any brief device-detected event.

Catheter ablation acts on tissue essential to the maintenance or initiation of the arrhythmia. In atrioventricular nodal re-entrant tachycardia or accessory-pathway tachycardia, it can eliminate a circumscribed component of the circuit and provide durable control, often avoiding chronic therapy. In focal atrial tachycardias and flutters, the target depends on the location of the focus or the path of the circuit. Probability of success and risk are not uniform: proximity to the normal conduction system, anatomy, previous procedures and congenital heart disease alter the difficulty. The choice should therefore refer to the actual mechanism and the center's experience.

In atrial fibrillation, pulmonary vein isolation is the foundation of ablation in many patients because these regions can provide the impulses that initiate the arrhythmia. The procedure may be offered after drug failure or intolerance and, in selected patients, also as the first rhythm-control strategy. Outcome depends on the duration of atrial fibrillation, atrial remodeling, comorbidities and individual characteristics; a recurrence does not necessarily mean that every benefit has been lost, but may require reassessment or further intervention. Control of weight, blood pressure, alcohol consumption and sleep-disordered breathing remains part of the pathway even after a technically successful procedure.

Radiofrequency, cryoenergy and pulsed-field ablation create lesions through different principles. The availability of new technologies does not eliminate the need for patient selection and procedural risk assessment. The ADVENT trial compared a pulsed-field technology with thermal techniques in patients with paroxysmal atrial fibrillation, demonstrating noninferiority for the main outcomes studied; this result is not equivalent to an absence of complications and does not establish universal superiority in every form of atrial fibrillation. Clinical judgment integrates evidence for the specific technology, anatomy, experience and patient goals, distinguishing short-term outcomes from the durability of control over time.

In ventricular arrhythmias, ablation may target an idiopathic focus, a scar-related circuit or regions sustaining repeated episodes. It is particularly important when tachycardias recur despite therapy, when drugs are not tolerated or when a high ectopic burden contributes to ventricular dysfunction. In the presence of scar, the procedure may require complex mapping and, at times, epicardial access. Reducing episodes and defibrillator therapies is a clinically relevant goal, but successful ablation does not automatically abolish the risk determined by the underlying heart disease and does not eliminate every indication for device protection.

A pacemaker treats the consequences of an inadequate heart rate or unreliable conduction. In sinus-node dysfunction, demonstrating that bradycardia or pauses are responsible for symptoms is central, and there is no single heart-rate or pause-duration threshold that always mandates implantation. In nonreversible advanced atrioventricular blocks, the reasoning is different and an indication may exist even without clearly recognized symptoms. Selection of the pacing mode considers atrial rhythm, residual conduction, ventricular function and expected pacing requirement; merely guaranteeing a minimum number of beats is not enough if useful coordination between the chambers is impaired.

Physiological pacing, through conduction-system pacing strategies or cardiac resynchronization in appropriate patients, aims to limit the effects of nonphysiological ventricular activation. The need depends mainly on ventricular function and the amount of pacing expected or already present. Not everyone who requires a pacemaker needs the same technology, and a more complex procedure does not automatically provide an advantage to every patient. Optimization also includes programming of chronotropic response, atrioventricular intervals and reduction of unnecessary pacing, avoiding pursuit of a technical parameter at the expense of hemodynamic function.

An implantable cardioverter-defibrillator detects and treats certain ventricular arrhythmias through antitachycardia pacing or shocks. Its indication derives from secondary-prevention criteria or from risk stratification for primary prevention specific to the heart disease. Previous arrest due to a ventricular arrhythmia, ventricular function, scar, specific genetic diagnoses and overall prognosis may contribute to the decision. A defibrillator does not necessarily prevent the onset of every episode and does not treat all causes of sudden death; moreover, it is not equivalent to an ordinary pacemaker. Expected benefit must be assessed together with comorbidities, life expectancy and the possibility of meaningful functional recovery.

Device programming influences the balance between protection and unnecessary therapies. Detection times, rate zones and discrimination algorithms are tailored to the clinical picture because supraventricular arrhythmias or noncardiac signals may trigger inappropriate therapies. Remote monitoring allows identification of events, parameter changes and system problems, but does not replace every clinical assessment and should not be understood as continuous emergency surveillance in all healthcare organizations. Patients need to know how alerts are managed and which symptoms instead require immediate access to healthcare services.

Atrioventricular junction ablation combined with pacing may be considered in selected patients with atrial fibrillation and unsatisfactory rate control despite other strategies. The procedure makes ventricular activation regular and controllable, but does not eliminate atrial fibrillation in the atria and results in pacing dependence. Assessment of embolic risk and selection of a pacing mode appropriate to ventricular function therefore remain relevant. This strategy has a different meaning from atrial fibrillation ablation and should be explained clearly, especially when the patient generically interprets every ablation as elimination of the same arrhythmia.

Arrhythmia-induced cardiomyopathy requires effective control of the electrical factor together with heart-failure treatment. When the rhythm or ectopic burden is responsible for a substantial part of the damage, recovery may develop over the following weeks or months; timing and extent vary according to duration of exposure and substrate. Improvement in ejection fraction supports a causal role of the arrhythmia, but does not necessarily demonstrate complete myocardial recovery. Recurrences may cause renewed deterioration and justify subsequent monitoring even when the patient no longer feels palpitations.

During pregnancy, hemodynamic and autonomic changes may increase the frequency of arrhythmias or make previously mildly symptomatic arrhythmias manifest. Management considers maternal condition, gestational age, heart disease and possible fetal effects of drugs simultaneously. An arrhythmia with maternal instability requires effective treatment without unjustified delay; elective strategies are instead planned with cardiology and obstetric expertise. Any need for a procedure is assessed case by case, with attention to exposure and available techniques. General principles remain valid, but pharmacological selection cannot be transferred automatically from the nonpregnant population.

In children, normal rates, prevalent mechanisms and hemodynamic consequences differ according to age; in adults with congenital heart disease, circuits related to anatomy and previous procedures may make treatment more complex. In older adults, frailty, renal impairment and polypharmacy particularly influence pharmacological and procedural safety. Chronological age, considered in isolation, does not determine the benefit of ablation or a device. The decision considers functional goals, probability of recurrence, availability of care and the ability to recognize or report symptoms, seeking a strategy sustainable in the person's real-life context.

Resumption of physical activity requires assessment of the specific diagnosis and risk. In many patients, regular and proportionate activity improves functional capacity and risk-factor control; in some cardiomyopathies or channelopathies, specific recommendations are necessary. It is not appropriate to prohibit all exercise solely on the basis of the word arrhythmia, nor to consider any activity safe because the patient feels well. In competitive sport, assessment integrates the response to exercise, underlying disease, treatment efficacy and characteristics of the sport, with an informed discussion of residual uncertainties.

Prognosis depends primarily on the substrate and on the type of event to be prevented. Many supraventricular tachycardias in hearts without structural abnormalities have a favorable prognosis and a high potential for definitive treatment; ventricular tachycardia arising from a scar signals a different problem even when well tolerated. In atrial fibrillation, embolic risk, heart failure and comorbidities contribute to outcomes independently of the intensity of palpitations. In sinus-node dysfunction, pacing is primarily directed at correcting symptoms and limitations attributable to bradycardia; it should not be presented as universal prevention of sudden death.

Follow-up assesses symptoms, rhythm recurrence, treatment safety, ventricular function and changes in the risk profile. The need for new recordings depends on the clinical question: documenting a recurrence, measuring ectopic burden or verifying functional recovery are different objectives. Therapy that is effective today may require adjustment when renal function, body weight, concomitant drugs or daily activity change. Continuity of care allows these transitions to be recognized before they translate into events, keeping planned surveillance distinct from the response to acute symptoms.

Shared decision-making is particularly important when several reasonable options exist. Frequency of attacks, willingness to take chronic therapy, probability of procedural success and tolerance of risk may lead to different choices despite the same diagnosis. The patient should know what outcome is expected, which problems may persist and how effectiveness will be measured. Quality of life is a legitimate clinical outcome, but should be considered together with prognostic goals: reducing fear of episodes is important, whereas discontinuing necessary protection solely because the rhythm appears regular may expose the patient to avoidable risk.

Complications

The complications of arrhythmias depend on the electrical disturbance, its duration and cardiovascular reserve, but also on the disease sustaining it. It is useful to distinguish damage directly caused by the rhythm from manifestations of concomitant heart disease and from treatment effects. The same person may have all of these elements: a tachycardia may worsen heart failure, the ventricular substrate may increase the risk of sudden death, and therapy may introduce a risk of bradycardia or bleeding. Correct attribution of cause allows targeted interventions to be selected and prevents a partial improvement from being interpreted as a solution to every problem.

Hemodynamic compromise may occur rapidly when the rhythm substantially reduces filling, output or chamber coordination. Extreme tachycardia shortens diastole and may increase pressures upstream of the ventricle; marked bradycardia reduces the number of effective ejections; atrioventricular dissociation may make the atrial contribution unfavorable. Signs include hypotension, hypoperfusion, oliguria, altered mental status and congestion. The relationship is not determined solely by heart rate: severe valvular disease or a stiff ventricle may make a rhythm poorly tolerated that another patient could withstand for a considerable time.

Heart failure may be precipitated by a new arrhythmia or aggravated by inadequate control of a previously known disorder. Loss of coordinated atrial contraction, irregularity of the ventricular response and an excessive rate may impair circulatory efficiency even before a cardiomyopathy specifically induced by the arrhythmia develops. In pre-existing heart failure, congestion and neurohormonal activation in turn facilitate new episodes. Effective treatment often requires acting on both processes: rate reduction alone may not resolve substantial congestion, whereas diuresis alone may leave active the electrical factor that continues to destabilize the patient.

Ventricular dysfunction associated with a persistent arrhythmia results from changes in contractility, calcium handling, metabolism and remodeling. In incessant tachycardias the relationship with rate is evident, but a high burden of premature beats may also impair the ventricle through irregularity and dyssynchrony. There is no burden threshold that perfectly separates all vulnerable patients from protected patients: morphology, site, duration of exposure and substrate contribute to risk. Follow-up of ventricular function is therefore guided by clinical probability, and recovery after treatment should be verified with comparable measurements.

Thromboembolism mainly concerns atrial arrhythmias in which mechanical atrial dysfunction, endocardial abnormalities and a predisposition to coagulation coexist. In atrial fibrillation, stasis in the left atrial appendage contributes to thrombus formation that can embolize to the brain or other territories. Age, previous events and comorbidities strongly modify individual risk. A person without palpitations may therefore require prevention, whereas a regular supraventricular tachycardia does not automatically carry the same problem. Atrial flutter also requires appropriate antithrombotic assessment, taking into account the frequent coexistence or subsequent development of atrial fibrillation.

Ischemic stroke may be the first manifestation of an unrecognized atrial arrhythmia. The search for atrial fibrillation after a cerebrovascular event should be proportionate to the context and may require monitoring longer than an occasional ECG. Detection of a very brief episode, however, raises a problem of causal and therapeutic interpretation: documenting coexistence does not always establish that the rhythm caused the event. Prevention should integrate overall vascular risk and the available evidence, distinguishing confirmed atrial fibrillation from doubtful signals or atrial episodes of still-uncertain significance.

Traumatic syncope adds the risk of fractures, head injury and loss of independence to the consequences of hypoperfusion. Potential severity also depends on the circumstances: an episode while driving, working at height or diving has different consequences from an event occurring while the patient is already lying down. After treatment of the arrhythmia, resumption of activities should consider the probability of recurrence and the cause actually demonstrated, in addition to the rules applicable to the setting. If a concomitant vasodepressor or orthostatic component is present, pacemaker implantation may correct bradycardia without eliminating every possibility of recurrent syncope.

Cardiac arrest represents the extreme consequence of some rhythm disturbances, especially ventricular fibrillation and pulseless ventricular tachycardia, but may also occur in conditions with severe bradyarrhythmia or electrical activity without effective circulation. Sudden cardiac death describes an outcome, not a single electrocardiographic mechanism. This distinction prevents attributing absolute protection against any terminal deterioration to a defibrillator. Prevention includes treatment of heart disease, recognition of high-risk phenotypes and device protection when indicated; during the event, prompt resuscitation and defibrillation for appropriate rhythms are decisive.

Electrical storm is a state of instability characterized by repeated episodes of sustained ventricular arrhythmia within a short interval, often with defibrillator therapies. In addition to the risk of circulatory deterioration, repeated shocks and fear increase sympathetic activation and may contribute to maintaining the instability. Management requires a rapid search for ischemia, heart failure, metabolic abnormalities and device problems, together with antiarrhythmic treatment, adrenergic control and sedation when indicated. In selected cases, ablation, hemodynamic support or autonomic modulation strategies become necessary in centers with appropriate expertise.

Proarrhythmia is the appearance or worsening of a rhythm disturbance caused by treatment. It may present as a new tachycardia, excessively prolonged QT interval, sinus slowing or conduction block. Some drugs may organize atrial fibrillation into flutter and, under unfavorable circumstances, permit a very rapid ventricular response; others may promote ventricular tachycardias in the presence of scar. Recognition requires attention to changes from the initial clinical picture because a new arrhythmia during therapy does not necessarily represent simple spontaneous progression of the disease.

Bleeding complications mainly concern antithrombotic strategies. Risk increases with factors such as previous bleeding, renal impairment, anemia, drug combinations and predisposing lesions. Assessment serves to correct modifiable factors and select appropriate treatment, without using a bleeding score as an automatic reason to withhold indicated prevention. When bleeding occurs, its site, severity, drug and time since the last dose guide management; the risk of prolonged interruption of anticoagulation must subsequently also be reassessed. The problem does not end when bleeding stops, but includes the patient's future protection.

Invasive procedures may cause vascular complications, bleeding, pericardial effusion or tamponade; specific consequences depend on the target and technique. Ablation near the conduction system may cause block requiring pacing; in left atrial procedures, embolic events and injury to adjacent structures are also relevant. Some complications are rare but serious and may present after discharge. Risk assessment should therefore refer to the specific procedure rather than to a generic percentage assigned to all ablations. Patient selection and team experience contribute to the safety profile.

Implantable devices may be complicated by pocket hematoma, infection, lead dislodgement or malfunction and, in certain situations, impairment of valvular function. Infection of a device system may require complex treatment including removal of the hardware, not merely prolonged antibiotic therapy. In patients with a defibrillator, inappropriate therapies may cause pain, fear and urgent healthcare visits; proper programming and review of electrograms help identify their cause. Device complications should be considered even many years after implantation, when parameters change or new symptoms appear.

Pacing-induced cardiomyopathy may develop in a proportion of patients exposed to a high burden of nonphysiological ventricular pacing. The problem depends on the activation sequence and myocardial susceptibility, not on a simple device malfunction. A progressive decline in ventricular function requires assessment of pacing percentage, pacing site, concomitant diseases and the possibility of a strategy more favorable to synchrony. Pacemaker syndrome, related to unfavorable hemodynamic coordination, may also cause symptoms despite a technically functioning system. Follow-up should therefore include the effect on the patient in addition to the electrical integrity of the implant.

Consequences for quality of life may be important even in arrhythmias with a low mortality risk. Unpredictable episodes, repeated emergency-department visits and fear of recurrence may restrict work, exercise and relationships. In defibrillator recipients, fear of further shocks may persist after control of the arrhythmia. A comprehensible explanation of the diagnosis, a clear plan for episodes and, when necessary, psychological support contribute to functional recovery. These interventions complement cardiological treatment and allow success to be assessed through resumption of activities as well as through the number of recorded events.

Prevention of complications ultimately requires clinical reassessment when symptoms or context change. The onset of syncope in a person previously affected only by palpitations, worsening exercise tolerance or new ventricular dysfunction changes the clinical question even if the name of the arrhythmia remains the same. Similarly, disappearance of palpitations after a procedure does not make follow-up of heart disease or reassessment of embolic risk unnecessary. Effective management follows the evolution of the disease while maintaining a verifiable relationship between the problem identified, the intervention chosen and the outcome achieved.